Mepenzolate

Mepenzolate is an antimuscarinic medication primarily used to treat peptic ulcers by reducing stomach acid secretion. It is the methylated version of N-Methyl-3-piperidyl benzilate. ^[1]

Mepenzolate

Clinical data
AHFS/Drugs.com	Consumer Drug Information
ATC code	A03AB12 (WHO)
Identifiers
IUPAC name 3-(2-hydroxy-2,2-diphenylacetoxy)-1,1-dimethylpiperidinium
CAS Number	25990-43-6 Y
PubChem CID	4057
ChemSpider	3917 N
UNII	ONW3LB39P7
KEGG	C07818
ChEMBL	ChEMBL524004 N
CompTox Dashboard (EPA)	DTXSID2046969
Chemical and physical data
Formula	C21H26NO3+
Molar mass	340.443 g·mol−1
NY (what is this?)  (verify)

Pharmacology

Mepenzolate works by blocking the action of acetylcholine on muscarinic receptors in the gastrointestinal tract. This action reduces the secretion of stomach acid and slows intestinal motility, making it useful in the management of peptic ulcers and other gastrointestinal disorders.

Chemical Structure

The chemical structure of Mepenzolate is characterized by the presence of a piperidyl group attached to a benzilate moiety, with an additional methyl group. This structure is similar to that of N-Methyl-3-piperidyl benzilate, but with a methylation that enhances its antimuscarinic properties.

Clinical Uses

Mepenzolate is primarily indicated for the treatment of peptic ulcers. It may also be used off-label for other conditions where reduction of gastrointestinal motility and secretion is desired.

Side Effects

Mepenzolate has several side effects. Common side effects of Mepenzolate include dry mouth, blurred vision, constipation, and urinary retention. These side effects are typical of antimuscarinic agents due to their action on muscarinic receptors throughout the body.